Pfizer Prevnar vaccine wins approval for ages 6-17

Sat Jan 26, 2013 3:41am IST

Related Topics

Stocks

   

(Reuters) - Pfizer Inc on Friday said U.S. regulators had approved wider use of its Prevnar 13 vaccine to prevent infections with pneumococcal bacteria, for children and adolescents aged 6 years to 17 years.

The product was already approved in the United States to prevent infections among children aged 6 weeks through 5 years. It is also approved for adults aged 50 and older.

The vaccine protects against infection with 13 strains of the Streptococcus pneumoniae bacterium. The bacterium can cause pneumonia, ear infections and other problems.

Prevnar 13 has annual sales of about $3.5 billion, making it Pfizer's third-biggest brand. It was approved in 2010, and has largely displaced an older vaccine called Prevnar, which protected against only 7 prevalent strains of the bacterium.

(Reporting by Ransdell Pierson; Editing by David Gregorio and Dan Grebler)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Ebola Outbreak

HEALTH SHOWCASE

Breast Cancer Fight

Breast Cancer Fight

Roche, Merck extend immunotherapy fight to breast cancer  Full Article 

Office Perks

Office Perks

Apple, Facebook will pay for female employees to freeze their eggs.  Full Article 

It's In The Genes

It's In The Genes

Genetic link to Danish happiness, says study.  Video 

Smoking Effects

Smoking Effects

Americans have 14 million smoking-related ailments: study.  Full Article 

Health Food

Health Food

Olive oil, nuts may help reverse heart risk factors.  Full Article 

Digital Doctors

Digital Doctors

China sees tech cure for healthcare woes.  Full Article 

Stem Cell Study

Stem Cell Study

Stem cells from human embryos prove safe, improve vision - study.  Full Article 

Shortages Impact

Shortages Impact

Shortages hinder Venezuela's battle against fever outbreaks  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage